Sanofi SA (SNY)
49.00
-0.36
(-0.73%)
USD |
NASDAQ |
Apr 26, 10:03
Sanofi Price to Book Value: 1.495 for April 26, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 1.506 |
| April 24, 2024 | 1.422 |
| April 23, 2024 | 1.455 |
| April 22, 2024 | 1.439 |
| April 19, 2024 | 1.413 |
| April 18, 2024 | 1.385 |
| April 17, 2024 | 1.407 |
| April 16, 2024 | 1.397 |
| April 15, 2024 | 1.411 |
| April 12, 2024 | 1.401 |
| April 11, 2024 | 1.422 |
| April 10, 2024 | 1.438 |
| April 09, 2024 | 1.450 |
| April 08, 2024 | 1.439 |
| April 05, 2024 | 1.442 |
| April 04, 2024 | 1.458 |
| April 03, 2024 | 1.463 |
| April 02, 2024 | 1.455 |
| April 01, 2024 | 1.473 |
| March 28, 2024 | 1.483 |
| March 27, 2024 | 1.512 |
| March 26, 2024 | 1.518 |
| March 25, 2024 | 1.508 |
| March 22, 2024 | 1.467 |
| March 21, 2024 | 1.456 |
| Date | Value |
|---|---|
| March 20, 2024 | 1.472 |
| March 19, 2024 | 1.449 |
| March 18, 2024 | 1.459 |
| March 15, 2024 | 1.473 |
| March 14, 2024 | 1.467 |
| March 13, 2024 | 1.472 |
| March 12, 2024 | 1.479 |
| March 11, 2024 | 1.475 |
| March 08, 2024 | 1.472 |
| March 07, 2024 | 1.466 |
| March 06, 2024 | 1.455 |
| March 05, 2024 | 1.449 |
| March 04, 2024 | 1.439 |
| March 01, 2024 | 1.443 |
| February 29, 2024 | 1.460 |
| February 28, 2024 | 1.464 |
| February 27, 2024 | 1.471 |
| February 26, 2024 | 1.471 |
| February 23, 2024 | 1.488 |
| February 22, 2024 | 1.458 |
| February 21, 2024 | 1.462 |
| February 20, 2024 | 1.429 |
| February 16, 2024 | 1.409 |
| February 15, 2024 | 1.415 |
| February 14, 2024 | 1.397 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.260
Minimum
Sep 27 2022
1.990
Maximum
Jun 22 2020
1.671
Average
1.685
Median
Price to Book Value Benchmarks
| AstraZeneca PLC | 5.943 |
| GSK PLC | 4.940 |
| Novo Nordisk A/S | 35.67 |
| Regeneron Pharmaceuticals Inc | 3.726 |
| Inhibrx Inc | 37.14 |
Price to Book Value Related Metrics
| PE Ratio | 20.91 |
| PS Ratio | 2.440 |
| Price | 49.00 |
| Earnings Yield | 4.78% |
| Market Cap | 122.36B |
| Operating PE Ratio | 10.90 |
| Normalized PE Ratio | 15.43 |